Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma

<div>Kaplan-Meier progression-free survival (PFS) analysis of four selected wavelet features. (a) The PFS analysis of feature 1. The PFS of groups A (&lt;0.320) and B (≥0.320) showed a significant difference. (b–d) The PFS analysis of features 2, 3, and 4. The PFS showed no significant difference between the A and B groups of each feature. Features 1, 2, 3, and 4 were wavelet-HLH_firstorder_kurtosis, wavelet-HLH_glcm_correlation, wavelet-HHL_firstorder_kurtosis, and wavelet-LLH_firstorder_mean, respectively.</div>

BioMed Research International

fig5

Figure 5

Figure 5: Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma 

Figure 5 | Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma 